GlassScriptPhysician profile
Lawrence S Bluth
NPI 1699785469
$15,487.69
in general payments reported to CMS, 2019-2025
65 companies · $3,851 in 2025
The $3,851 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,983 · 2020: $806 · 2021: $1,340 · 2022: $2,034 · 2023: $2,759 · 2024: $2,715 · 2025: $3,851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,324.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,739.09 | 2019-2025 | Qulipta, Ubrelvy, Duopa |
| Novartis Pharmaceuticals Corporation | $1,481.07 | 2019-2025 | |
| Pfizer INC. | $1,038.50 | 2023-2025 | |
| Emd Serono, INC. | $688.08 | 2019-2025 | Mavenclad |
| Ucb, INC. | $642.78 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Genzyme Corporation | $619.13 | 2019-2025 | |
| Sk Life Science, INC. | $597.60 | 2021-2024 | |
| Tg Therapeutics, INC. | $591.14 | 2023-2025 | |
| Biogen, INC. | $535.15 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Alexion Pharmaceuticals, INC. | $506.74 | 2019-2025 | Ultomiris, Soliris |
| Amgen INC. | $453.28 | 2019-2025 | Uplizna |
| Celgene Corporation | $424.72 | 2022-2024 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $336.86 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $323.27 | 2019-2025 | Rytary, Crexont |
| Acorda Therapeutics, INC | $277.82 | 2019-2020 |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $277.64 | 2019-2025 | Nourianz |
| Lundbeck LLC | $263.90 | 2021-2025 | Vyepti |
| Horizon Therapeutics Plc | $211.86 | 2021-2023 | Uplizna |
| Biohaven Pharmaceutical Holding Company LTD. | $211.23 | 2022 | |
| Mdd US Operations, LLC | $202.04 | 2022-2025 | Gocovri |
| Takeda Pharmaceuticals U.S.A., INC. | $199.66 | 2023-2025 | Hyqvia |
| Eisai INC. | $199.46 | 2021-2025 | |
| Argenx US, INC. | $187.76 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Allergan, INC. | $184.47 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $180.93 | 2021-2025 | Wainua, Andexxa |
| Genentech USA, INC. | $180.57 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Tanabe Pharma America, INC. | $169.57 | 2020-2025 | Radicava |
| Neurocrine Biosciences, INC. | $166.91 | 2019-2023 | Ongentys, Ingrezza |
| Acadia Pharmaceuticals INC | $166.17 | 2023-2025 | Nuplazid |
| Akcea Therapeutics, INC. | $156.85 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $154.24 | 2019-2025 | Qelbree |
| Octapharma USA, INC. | $148.10 | 2024-2025 | Panzyga |
| Grifols USA, LLC | $136.61 | 2020-2025 | Gamunex-C |
| Ge Healthcare | $129.79 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $123.19 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $118.55 | 2021 | |
| Janssen Pharmaceuticals, INC | $109.66 | 2021-2023 | Ponvory |
| Arbor Pharmaceuticals, INC. | $109.04 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $91.73 | 2021-2025 | Keveyis |
| Cycle Pharmaceuticals INC | $83.84 | 2025 | Bafiertam, Tascenso Odt |
| Adamas Pharmaceuticals, INC. | $83.45 | 2019-2021 | |
| Axsome Therapeutics, INC. | $74.09 | 2025 | Symbravo |
| Abbott Laboratories | $73.49 | 2021-2023 | Infinity |
| Catalyst Pharmaceuticals, INC. | $69.78 | 2022-2025 | Firdapse |
| Avanir Pharmaceuticals, INC. | $66.52 | 2019 | |
| Lilly USA, LLC | $64.80 | 2025 | Kisunla |
| Amylyx Pharmaceuticals, INC. | $61.75 | 2023 | Relyvrio |
| Vanda Pharmaceuticals INC. | $53.46 | 2025 | Ponvory |
| Alnylam Pharmaceuticals INC. | $53.29 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $51.55 | 2022-2023 | |
| Neurelis, INC. | $37.07 | 2024 | Valtoco |
| Baxter Healthcare | $37.07 | 2025 | |
| Strongbridge US INC. | $36.59 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $35.69 | 2022 | |
| Kedrion Biopharma, INC. | $34.16 | 2025 | Albuked, Koate, Rhogam Ultra-Filtered Plus |
| Mallinckrodt Hospital Products INC. | $31.06 | 2021 | |
| Glaxosmithkline, LLC. | $27.92 | 2022 | |
| Avion Pharmaceuticals | $27.13 | 2022 | |
| Mallinckrodt Enterprises LLC | $25.84 | 2019 | |
| Insightec,INC | $24.85 | 2024 | Exablate |
| Vertical Pharmaceuticals, LLC | $24.01 | 2019 | |
| Csl Behring | $22.42 | 2019 | |
| Invivyd INC | $21.35 | 2025 | Pemgarda |
| Springworks Therapeutics, INC. | $17.37 | 2025 | Gomekli |
| Medtronic USA, INC. | $13.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Bluth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.